Detalles de la búsqueda
1.
From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.
BMC Cancer
; 15: 842, 2015 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26531748
2.
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Drugs R D
; 21(4): 399-406, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34562258
3.
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
JCO Precis Oncol
; 5: 215-226, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34994597
4.
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.
NPJ Precis Oncol
; 5(1): 59, 2021 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34162980
5.
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.
Mol Oncol
; 15(1): 104-115, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32750212
6.
Sustained Tumor Control With MAPK Inhibition in BRAF V600-Mutant Adult Glial and Glioneuronal Tumors.
Neurology
; 97(7): e673-e683, 2021 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34088874
7.
Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Eur J Cancer
; 95: 75-84, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29635147
8.
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
ESMO Open
; 3(3): e000339, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29636991
9.
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Clin Cancer Res
; 18(17): 4794-805, 2012 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22767668
10.
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
Eur J Cancer
; 47(10): 1468-75, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21482105
11.
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
Target Oncol
; 5(1): 65-72, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20361265
Resultados
1 -
11
de 11
1
Próxima >
>>